FDA.reportPublic FDA data

solifenacin succinate 5 MG per 5 ML Oral Suspension

RxCUI
2375321
RxNorm name
solifenacin succinate 5 MG per 5 ML Oral Suspension
Display name
solifenacin succinate 5 MG per 5 ML Oral Suspension
Full name
solifenacin succinate 5 MG per 5 ML Oral Suspension
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:24

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
e0300384-e980-45d5-8ed4-48a2618671aesolifenacin succinate 5 MG in 5 mL Oral Suspension [PSN] · solifenacin succinate 1 MG/ML Oral Suspension [SCD] · solifenacin succinate 5 MG per 5 ML Oral Suspension [SY]34These highlights do not include all the information needed to use VESICARE LS safely and effectively. See full prescribing information for VESICARE LS. VESICARE LS ® (solifenacin succinate) oral suspension Initial U.S. Approval: 200420221031